Ellex/Quantel Medical will present a new intense pulsed light (IPL) system for dry eye disease on its virtual booth at the RANZCO Congress later this month.
This week on 9 February the company, which is part of Lumibird Medical group, announced the launch of the C.STIM IPL system. It is being described as the new generation of IPL designed by Quantel Medical to treat dry eye disease.
“Drawing on Quantel Medical’s years of experience in intense pulsed light in dermatology, we have now developed a new IPL device exclusively for use in ophthalmology, designed and manufactured by the Lumibird Medical group,” Mr Jean-Marc Gendre, CEO of Lumibird Medical, stated.
“We are convinced that this new premium product of our dry eye range will bring an innovative therapeutic solution to ophthalmologists confronted with the daily challenge of dry eye treatment.”
With dry eye affecting more than 700 million people globally, the company stated it is one of the most common pathologies in ophthalmic visits. Dry eye treatment is also a key consideration in many specialties such as glaucoma, refractive and cataract surgeries, and contact lenses, among others.
The Quantel Medical system has been designed in-house, and aims to treat the root causes of dry eye, including meibomian gland dysfunction, inflammation and demodex.
“Thanks to the unique Stim-ULI technology (Uniform Light Intensity), C.STIM offers the best combination of clinical efficacy and patient comfort,” Ms Delphine Southon, Quantel Medical’s dry eye product manager, said.
C.STIM has been designed to combine cutting-edge technology with a sleek, robust and ergonomic design. The device integrates the best technological features to guarantee efficacy, safety, ergonomics and to offer a “plug and play” product that is easily delegable, Quantel Medical stated.
Delegates attending the 52nd RANZCO Virtual Meeting (26 February – 1 March 2022), can view the C.STIM IPL System on the Ellex/Quantel Medical – Lumibird Medical virtual booth.
Lumibird Medical is the medical holding of the Lumibird Group, a global leader in the development of solid-state lasers for scientific and industrial use. It comprises Quantel Medical (France and Polska) and Ellex (Australia, Japan and US), along with Optotek Medical in Slovenia and Lumibird Medical Nordics (Sweden, Finland and Norway).
Lumibird and Quantel Medical acquired the laser and ultrasound business of Australian company Ellex Medical Lasers in July 2020 for $100 million, along with the Ellex brand. The remainder of the Ellex business at the time – focussed on MIGS for glaucoma and age-related macular degeneration – has formed under a new company called Nova Eye Medical.
More reading
Ellex/Quantel Medical merger takes shape
ACCC concludes investigation, clears Ellex-Lumibird deal
Aussie-led dry eye registry paints fuller picture of disease landscape
